Cryoport, Inc.

NasdaqCM:CYRX Aktierapport

Börsvärde: US$519.5m

Cryoport Förvaltning

Förvaltning kriterier kontrolleras 3/4

Cryoport VD är Jerry Shelton, utsedd i Nov 2012, har en mandatperiod på 13.5 år. totala årliga ersättningen är $ 2.38M, bestående av 40.7% lön 59.3% bonusar, inklusive företagsaktier och optioner. äger direkt 2.45% av företagets aktier, värda $ 12.74M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 6.3 år respektive 11.9 år.

Viktig information

Jerry Shelton

Verkställande direktör

US$2.4m

Total ersättning

VD-lön i procent40.74%
Anställning som VD13.5yrs
Ägande av VD2.5%
Ledningens genomsnittliga anställningstid6.3yrs
Styrelsens genomsnittliga mandatperiod11.9yrs

Senaste uppdateringar av ledningen

Recent updates

CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook

Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.

CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns

Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.

CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential

Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.

CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential

Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).

CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects

Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).

CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects

Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).

CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside

Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.

CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects

Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.

CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects

Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.

CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside

Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.

CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery

The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.

CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound

Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.

Cold Chain Expansion Will Support Cell And Gene Therapies

Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.

Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet

Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet

Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable

May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable

Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?

Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
User avatar

New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply

Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price

Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower

Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower

Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)

Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?

The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More

Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Jul 22
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Jun 25
Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport Tanks On Chilling Results And Bad Decisions

Mar 14

Analys av ersättningar till VD

Hur har Jerry Shelton:s ersättning förändrats jämfört med Cryoport:s resultat?
DatumTotal ersättningLönFöretagets resultat
Dec 31 2025US$2mUS$968k

-US$42m

Sep 30 2025n/an/a

-US$61m

Jun 30 2025n/an/a

-US$50m

Mar 31 2025n/an/a

-US$117m

Dec 31 2024US$2mUS$921k

-US$113m

Sep 30 2024n/an/a

-US$158m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$117m

Dec 31 2023US$2mUS$866k

-US$93m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022US$2mUS$792k

-US$45m

Sep 30 2022n/an/a

-US$296m

Jun 30 2022n/an/a

-US$297m

Mar 31 2022n/an/a

-US$293m

Dec 31 2021US$5mUS$713k

-US$284m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$78m

Mar 31 2021n/an/a

-US$77m

Dec 31 2020US$5mUS$613k

-US$75m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$23m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$4mUS$600k

-US$18m

Ersättning vs marknad: Jerry s total kompensation ($USD 2.38M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.50M ).

Ersättning vs inkomst: Ersättningen för Jerry har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Jerry Shelton (80 yo)

13.5yrs
Anställning
US$2,375,524
Kompensation

Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Jerrell Shelton
Chairman13.5yrsUS$2.38m2.45%
$ 12.7m
Robert Stefanovich
Senior VP14.9yrsUS$1.12m0.56%
$ 2.9m
Edward Zecchini
Senior VP and Chief Digital & Technology Officer2.3yrsUS$1.09m0.22%
$ 1.1m
Mark Sawicki
Senior VP & Chief Scientific Officer5.7yrsUS$986.06k0.20%
$ 1.1m
Thomas Heinzen
Vice President of Corporate Development & Investor Relationsno datainga uppgifteringa uppgifter
Tony Ippolito
VP, General Counsel & Corporate Secretaryno datainga uppgifteringa uppgifter
Kylie Crowe
Vice President of Global Human Resources & Organizational Developmentno datainga uppgifteringa uppgifter
Phil Wilson
Chief Operating Officer of Cryoport Systems6.3yrsinga uppgifteringa uppgifter
6.3yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder

Erfaren ledning: CYRX s ledningsgrupp är erfaren och erfaren ( 6.3 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Jerrell Shelton
Chairman13.6yrsUS$2.38m2.45%
$ 12.7m
Edward Zecchini
Senior VP and Chief Digital & Technology Officer12.7yrsUS$1.09m0.22%
$ 1.1m
Linda Baddour
Independent Director5.2yrsUS$421.79k0.12%
$ 597.7k
William Taaffe
Member of Commercial Advisory Board13.3yrsinga uppgifteringa uppgifter
Robert Hariri
Independent Director10.7yrsUS$419.07k0.10%
$ 530.7k
Ram Jagannath
Independent Director5.6yrsUS$70.00kinga uppgifter
Richard Kriss
Member of Advisory Board18.3yrsinga uppgifteringa uppgifter
Larry O'Toole
Member of Advisory Boardno datainga uppgifteringa uppgifter
Ramkumar Mandalam
Independent Director11.9yrsUS$430.97k0.11%
$ 595.6k
Daniel Hancock
Independent Director7.3yrsUS$395.07k0.12%
$ 607.6k
11.9yrs
Genomsnittlig anställningstid
66.5yo
Genomsnittlig ålder

Erfaren styrelse: CYRX s styrelse är rutinerade och erfaren ( 11.9 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/03 21:08
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Cryoport, Inc. bevakas av 14 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Andrew D'SilvaB. Riley Securities, Inc.
Yuan ZhiB. Riley Securities, Inc.